Nitazoxanide use as part of an empiric multi-drug regimen in treating children with suspected helicobacter pylori infection

Case Reports in Gastroenterology

Volumn 9, Issue 1, 2015, Pages 36-42

  Ramos Soriano, Asuncion G ^a   Black, Jimmy ^b  

^a Laredo Medical Center   (United States)

^b Atom Strategic Consulting LLC   (United States)

Author keywords

Children; Gastritis; Helicobacter pylori infection; Multi drug regimen; Nitazoxanide

Indexed keywords

AZITHROMYCIN; CEFDINIR; CEFIXIME; CEFTIBUTEN; NITAZOXANIDE; PROTON PUMP INHIBITOR;

ABDOMINAL CRAMP; ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; ENDOSCOPY; FEMALE; HELICOBACTER INFECTION; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; VOMITING;

EID: 84929461848     PISSN: None     EISSN: 16620631     Source Type: Journal    
DOI: 10.1159/000375116     Document Type: Article

References (18)

1. Blaser MJ: Who are we? Indigenous microbes and the ecology of human diseases. EMBO Rep 2006;7: 956-960.
2. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY: Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001;161: 1217-1220.
3. Mégraud F: H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53: 1374-1384.
4. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI: Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003;9:565-572.
5. Szajewska H, Mrukowicz JZ: Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001;33(suppl 2):S17-S25.
6. McColl KE: Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597-1604.
7. Rossignol JF, Abu-Zekry M, Hussein A, Santoro MG: Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 2006;368:124-129.
8. Rossignol JF, El-Gohary YM: Nitazoxanide in the treatment of viral gastroenteritis: a randomized doubleblind placebo-controlled clinical trial. Aliment Pharmacol Ther 2006;24:1423-1430.
9. Francois F, Blaser MJ: Improving Helicobacter pylori eradication regimens. Ann Intern Med 2006;144: 140-141.
10. Gisbert JP, González L, Calvet X, García N, López T, Roqué M, Gabriel R, Pajares JM: Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000;14:1319-1328.
11. Laine L, Fennerty MB, Osato M, Sugg J, Suchower L, Probst P, Levine JG: Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, doubleblind trials. Am J Gastroenterol 2000;95:3393-3398.
12. Buta N, Tanih NF, Ndip RN: Increasing trend of Metronidazole resistance in the treatment of Helicobacter pylori infection. A global challenge. Afr J Biotechnol 2010;9:1115-1121.
13. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M: A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011;106:1970-1975.
14. Rossignol JF, Cavier R: A new derivative of 2-benzamido 5-nitrothiazoles. Chem Abstr 1975;83:28216.
15. Arya SC: Nitazoxanide as a broad-spectrum antiparasitic agent. J Infect Dis 2002;185:1692.
16. Dubreuil L, Houcke I, Mouton Y, Rossignol JF: In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996;40:2266-2270.
17. Alinia Prescribing Information. Romark Pharmaceuticals, June 2005.
18. Siddiq DM, Koo HL, Adachi JA, Viola GM: Norovirus gastroenteritis successfully treated with nitazoxanide. J Infect 2011;63:394-397.